Update of the management of chronic psoriasis: new approaches and emerging treatment options

References

• GriffithsCEBarkerJNPathogenesis and clinical features of psoriasisLancet200737026327117658397
   PubMed Web of Science ®Google Scholar
• HenselerTChristophersEPsoriasis of early and late onset: characterization of two types of psoriasis vulgarisJ Am Acad Dermatol1985134504564056119
   PubMed Web of Science ®Google Scholar
• de KorteJSprangersMAMombersFMQuality of life in patients with psoriasis: a systematic literature reviewJ Investig Dermatol Symp Proc200494047
   Google Scholar
• GuptaMAGuptaAKDepression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasisBr J Dermatol19981398468509892952
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRExumMLPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol19994140140710459113
   PubMed Web of Science ®Google Scholar
• MartinBAChalmersRJTelferNRHow great is the risk of further psoriasis following a single episode of acute guttate psoriasis?Arch Dermatol19961327177188651734
   PubMedGoogle Scholar
• AsumalahtiKAmeenMSuomelaSGenetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosisJ Invest Dermatol200312062763212648227
   PubMed Web of Science ®Google Scholar
• CohenMRRedaDJCleggDOBaseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative SpondyloarthropathiesJ Rheumatol1999261752175610451073
   PubMed Web of Science ®Google Scholar
• McGonagleDBenjaminMTanALThe pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all?Curr Opin Rheumatol20092134034719424069
   PubMed Web of Science ®Google Scholar
• ZachariaeHPrevalence of joint disease in patients with psoriasis: implications for therapyAm J Clin Dermatol2003444144712814334
   PubMed Web of Science ®Google Scholar
• GottliebABMeasePJMark JacksonJClinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ officesJ Dermatolog Treat20061727928717092858
   PubMed Web of Science ®Google Scholar
• BrockbankJESteinMSchentagCTDactylitis in psoriatic arthritis: a marker for disease severity?Ann Rheum Dis2005648890
   Web of Science ®Google Scholar
• MollJMWrightVPsoriatic arthritisSemin Arthritis Rheum1973355784581554
   PubMedGoogle Scholar
• TaylorWGladmanDHelliwellPClassification criteria for psoriatic arthritis: development of new criteria from a large international studyArthritis Rheum2006542665267316871531
   PubMed Web of Science ®Google Scholar
• NajarianDJGottliebABConnections between psoriasis and Crohn’s diseaseJ Am Acad Dermatol20034880582112789169
   PubMed Web of Science ®Google Scholar
• BrophySTaylorGBlakeDThe interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritisJ Rheumatol2003302054205812966615
   PubMed Web of Science ®Google Scholar
• McDonaldCJCalabresiPPsoriasis and occlusive vascular diseaseBr J Dermatol197899469475708620
   PubMed Web of Science ®Google Scholar
• MenterAKormanNJElmetsCAGuidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agentsJ Am Acad Dermatol2009614518519493586
   PubMed Web of Science ®Google Scholar
• MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol20085882685018423260
   PubMed Web of Science ®Google Scholar
• KaufmannRBibbyAJBissonnetteRA new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgarisDermatology200220538939312444337
   PubMed Web of Science ®Google Scholar
• KragballeKAustadJBarnesLA 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgarisBr J Dermatol20061541155116016704648
   PubMed Web of Science ®Google Scholar
• LugerTACambazardFLarsenFGA study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasisDermatology200821732132818787325
   PubMed Web of Science ®Google Scholar
• JemecGBGanslandtCOrtonneJPA new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trialJ Am Acad Dermatol20085945546318694678
   PubMed Web of Science ®Google Scholar
• LebwohlMFreemanAKChapmanMSTacrolimus ointment is effective for facial and intertriginous psoriasisJ Am Acad Dermatol20045172373015523350
   PubMed Web of Science ®Google Scholar
• GribetzCLingMLebwohlMPimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized studyJ Am Acad Dermatol20045173173815523351
   PubMed Web of Science ®Google Scholar
• BergerTGDuvicMVan VoorheesASThe use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task ForceJ Am Acad Dermatol20065481882316635663
   PubMed Web of Science ®Google Scholar
• ThamSNGangeRWParrishJAUltraviolet-B treatment of psoriasis in patients with concomitant vitiligoArch Dermatol198712326273800418
   PubMedGoogle Scholar
• YonesSSPalmerRAGaribaldinosTTRandomized double-blind trial of the treatment of chronic plaque psoriasis:efficacy of psoralen-UV-A therapy vs narrowband UV-B therapyArch Dermatol200614283684216847198
   PubMedGoogle Scholar
• GriffithsCEChristophersEBarkerJNA classification of psoriasis vulgaris according to phenotypeBr J Dermatol200715625826217223864
   PubMed Web of Science ®Google Scholar
• GladmanDDPsoriatic arthritisDermatol Ther200922405519222516
   PubMed Web of Science ®Google Scholar
• SandhuKKaurIKumarBEfficacy and safety of cyclosporine versus methotrexate in severe psoriasis:a study from north IndiaJ Dermatol20033045846312810993
   PubMed Web of Science ®Google Scholar
• HeydendaelVMSpulsPIOpmeerBCMethotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasisN Engl J Med200334965866512917302
   PubMed Web of Science ®Google Scholar
• FlytstromIStenbergBSvenssonAMethotrexate vs. ciclosporin in psoriasis:effectiveness, quality of life and safety. A randomized controlled trialBr J Dermatol200815811612117986302
   PubMed Web of Science ®Google Scholar
• SauratJHStinglGDubertretLEfficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION)Br J Dermatol200815855856618047523
   PubMed Web of Science ®Google Scholar
• RoenigkHHJrAuerbachRMaibachHMethotrexate in psoriasis:consensus conferenceJ Am Acad Dermatol1998384784859520032
   PubMed Web of Science ®Google Scholar
• ChalmersRJKirbyBSmithAReplacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate:a multicentre audit and health economic analysisBr J Dermatol200515244445015787812
   PubMed Web of Science ®Google Scholar
• BerendsMASnoekJde JongEMBiochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients:Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosisLiver Int20072763964517498249
   PubMed Web of Science ®Google Scholar
• HoVCGriffithsCEBerth-JonesJIntermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a. 2-year cohort studyJ Am Acad Dermatol20014464365111260540
   PubMed Web of Science ®Google Scholar
• HoVCGriffithsCEAlbrechtGIntermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a. 1-year multicentre, randomized study. The PISCES Study GroupBr J Dermatol199914128329110468801
   PubMed Web of Science ®Google Scholar
• KooJA randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study GroupBr J Dermatol199813988959764154
   PubMed Web of Science ®Google Scholar
• ThaciDBrautigamMKaufmannRBody-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised studyDermatology200220538338812444336
   PubMed Web of Science ®Google Scholar
• ReitamoSSpulsPSassolasBEfficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis:a randomized controlled trialBr J Dermatol200114543844511531834
   PubMed Web of Science ®Google Scholar
• GriffithsCEDubertretLEllisCNCiclosporin in psoriasis clinical practice:an international consensus statementBr J Dermatol2004150Suppl 67112315115441
   PubMed Web of Science ®Google Scholar
• ShupackJAbelEBauerECyclosporine as maintenance therapy in patients with severe psoriasisJ Am Acad Dermatol1997364234329091474
   PubMed Web of Science ®Google Scholar
• MrowietzUFarberLHenneicke-von ZepelinHHLong-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis:results of a multicenter study. German Multicenter StudyJ Am Acad Dermatol1995334704757657870
   PubMed Web of Science ®Google Scholar
• LoweNJPrystowskyJHBourgetTAcitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin aloneJ Am Acad Dermatol1991245915941827799
   PubMed Web of Science ®Google Scholar
• Van ZanderJOrlowSJEfficacy and safety of oral retinoids in psoriasisExpert Opin Drug Saf2005412913815709903
   PubMedGoogle Scholar
• TanewAGuggenbichlerAHonigsmannHPhotochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison studyJ Am Acad Dermatol1991256826841838750
   PubMed Web of Science ®Google Scholar
• LebwohlMDrakeLMenterAConsensus conference:acitretin in combination with UVB or PUVA in the treatment of psoriasisJ Am Acad Dermatol20014554455311568745
   PubMed Web of Science ®Google Scholar
• YoungHSSummersAMReadIRInteraction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasisJ Invest Dermatol200612645345916385345
   PubMed Web of Science ®Google Scholar
• DiazBVLenoirMCLadouxARegulation of vascular endothelial growth factor expression in human keratinocytes by retinoidsJ Biol Chem200027564265010617662
   PubMed Web of Science ®Google Scholar
• SchweckendiekW[Treatment of psoriasis vulgaris.]Med Monatsschr195913103413643669
   PubMedGoogle Scholar
• TreumerFZhuKGlaserRDimethylfumarate is a potent inducer of apoptosis in human T cellsJ Invest Dermatol20031211383138814675187
   PubMed Web of Science ®Google Scholar
• HoefnagelJJThioHBWillemzeRLong-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasisBr J Dermatol200314936336912932244
   PubMed Web of Science ®Google Scholar
• MrowietzUChristophersEAltmeyerPTreatment of psoriasis with fumaric acid esters:results of a prospective multicentre study. German Multicentre StudyBr J Dermatol19981384564609580799
   PubMed Web of Science ®Google Scholar
• HarriesMJChalmersRJGriffithsCEFumaric acid esters for severe psoriasis:a retrospective review of 58 casesBr J Dermatol200515354955116120141
   PubMed Web of Science ®Google Scholar
• SmithCHAnsteyAVBarkerJNBritish Association of Dermatologists guidelines for use of biological interventions in psoriasis. 2005Br J Dermatol200515348649716120132
   PubMed Web of Science ®Google Scholar
• LebwohlMBagelJGelfandJMFrom the Medical Board of the National Psoriasis Foundation:monitoring and vaccinations in patients treated with biologics for psoriasisJ Am Acad Dermatol2008589410517980456
   PubMed Web of Science ®Google Scholar
• SmithCHAnsteyAVBarkerJNBritish Association of Dermatologists’ guidelines for biologic interventions for psoriasis. 2009Br J Dermatol2009161987101919857207
   PubMed Web of Science ®Google Scholar
• AveryRKVaccination of the immunosuppressed adult patient with rheumatologic diseaseRheum Dis Clin North Am19992556758410467629
   PubMed Web of Science ®Google Scholar
• AveryRKImmunizations in adult immunocompromised patients:which to use and which to avoidCleve Clin J Med20016833734811326813
   PubMed Web of Science ®Google Scholar
• FominICaspiDLevyVVaccination against influenza in rheumatoid arthritis:the effect of disease modifying drugs, including TNF alpha blockersAnn Rheum Dis20066519119416014674
   PubMed Web of Science ®Google Scholar
• KapetanovicMCSaxneTNilssonJAInfluenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patientsRheumatology (Oxford)20074660861117114801
   PubMed Web of Science ®Google Scholar
• YamauchiPSGindiVLoweNJThe treatment of psoriasis and psoriatic arthritis with etanercept:practical considerations on monotherapy, combination therapy, and safetyDermatol Clin20042244945915450340
   PubMed Web of Science ®Google Scholar
• KruegerGGElewskiBPappKPatients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trialJ Am Acad Dermatol200654S11211916488321
   PubMed Web of Science ®Google Scholar
• MooreAGordonKBKangSA randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisJ Am Acad Dermatol20075659860317113190
   PubMed Web of Science ®Google Scholar
• PappKATyringSLahfaMA global phase III randomized controlled trial of etanercept in psoriasis:safety, efficacy, and effect of dose reductionBr J Dermatol20051521304131215948997
   PubMed Web of Science ®Google Scholar
• TyringSGottliebAPappKEtanercept and clinical outcomes, fatigue, and depression in psoriasis:double-blind placebo-controlled randomised phase III trialLancet2006367293516399150
   PubMed Web of Science ®Google Scholar
• GisondiPDel GiglioMCotenaCCombining etanercept and acitretin in the therapy of chronic plaque psoriasis:a. 24-week, randomized, controlled, investigator-blinded pilot trialBr J Dermatol20081581345134918410408
   PubMed Web of Science ®Google Scholar
• ZachariaeCMorkNJReunalaTThe combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapyActa Derm Venereol20088849550118779890
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trialLancet200436367568115001324
   PubMed Web of Science ®Google Scholar
• CohenJDZaltniSKaiserMJSecondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritisAnn Rheum Dis20046320921014722213
   PubMed Web of Science ®Google Scholar
• PallerASSiegfriedECLangleyRGEtanercept treatment for children and adolescents with plaque psoriasisN Engl J Med200835824125118199863
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOPappKInfliximab induction and maintenance therapy for moderate-to-severe psoriasis:a phase III, multicentre, double-blind trialLancet20053661367137416226614
   PubMed Web of Science ®Google Scholar
• MenterAFeldmanSRWeinsteinGDA randomized comparison of continuous vs. intermittent infliximab maintenance regimens over. 1 year in the treatment of moderate-to-severe plaque psoriasisJ Am Acad Dermatol200756 31e11517097378
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOPappKImprovement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis:a randomized controlled trialBr J Dermatol20061541161116816704649
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOWuYInfliximab treatment improves productivity among patients with moderate-to-severe psoriasisEur J Dermatol20071738138617673380
   PubMed Web of Science ®Google Scholar
• MenterATyringSKGordonKAdalimumab therapy for moderate to severe psoriasis:A randomized, controlled phase III trialJ Am Acad Dermatol20085810611517936411
   PubMed Web of Science ®Google Scholar
• GordonKBLangleyRGLeonardiCClinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyJ Am Acad Dermatol20065559860617010738
   PubMed Web of Science ®Google Scholar
• RevickiDAMenterAFeldmanSAdalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III studyHealth Qual Life Outcomes200867518831744
   PubMed Web of Science ®Google Scholar
• SchmittJZhangZWozelGEfficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis:meta-analysis of randomized controlled trialsBr J Dermatol200815951352618627372
   PubMed Web of Science ®Google Scholar
• GottliebABLeonardiCLGoffeBSEtanercept monotherapy in patients with psoriasis:a summary of safety, based on an integrated multistudy databaseJ Am Acad Dermatol200654S92S10016488335
   PubMed Web of Science ®Google Scholar
• LecluseLLPiskinGMekkesJRReview and expert opinion on prevention and treatment of infliximab-related infusion reactionsBr J Dermatol200815952753618627374
   PubMed Web of Science ®Google Scholar
• LeeJHSlifmanNRGershonSKLife-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanerceptArthritis Rheum2002462565257012384912
   PubMed Web of Science ®Google Scholar
• SlifmanNRGershonSKLeeJHListeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agentsArthritis Rheum20034831932412571839
   PubMed Web of Science ®Google Scholar
• PetersonJRHsuFCSimkinPAEffect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infectionAnn Rheum Dis2003621078108214583571
   PubMed Web of Science ®Google Scholar
• OstuniPBotsiosCPunziLHepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexateAnn Rheum Dis20036268668712810441
   PubMed Web of Science ®Google Scholar
• LokASMcMahonBJChronic hepatitis BHepatology20074550753917256718
   PubMed Web of Science ®Google Scholar
• ChungSJKimJKParkMCReactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapyJ Rheumatol2009362416242019797507
   PubMed Web of Science ®Google Scholar
• GardamMAKeystoneECMenziesRAnti-tumour necrosis factor agents and tuberculosis risk:mechanisms of action and clinical managementLancet Infect Dis2003314815512614731
   PubMed Web of Science ®Google Scholar
• LimWSPowellRJJohnstonIDTuberculosis and treatment with infliximabN Engl J Med200234662362611856805
   PubMedGoogle Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med20013451098110411596589
   PubMed Web of Science ®Google Scholar
• DommSCinatlJMrowietzUThe impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections:a review of the literatureBr J Dermatol20081591217122818945310
   PubMed Web of Science ®Google Scholar
• KwonHJCoteTRCuffeMSCase reports of heart failure after therapy with a tumor necrosis factor antagonistAnn Intern Med200313880781112755552
   PubMed Web of Science ®Google Scholar
• ListingJStrangfeldAKekowJDoes tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?Arthritis Rheum20085866767718311816
   PubMed Web of Science ®Google Scholar
• ShakoorNMichalskaMHarrisCADrug-induced systemic lupus erythematosus associated with etanercept therapyLancet200235957958011867114
   PubMed Web of Science ®Google Scholar
• NormanRGreenbergRGJacksonJMCase reports of etanercept in inflammatory dermatosesJ Am Acad Dermatol200654S139S14216488329
   PubMed Web of Science ®Google Scholar
• GeborekPBladstromATuressonCTumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomasAnn Rheum Dis20056469970315695534
   PubMed Web of Science ®Google Scholar
• AsklingJForedCMBrandtLRisks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonistsAnn Rheum Dis2005641421142615829572
   PubMed Web of Science ®Google Scholar
• BongartzTSuttonAJSweetingMJAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies:systematic review and meta-analysis of rare harmful effects in randomized controlled trialsJAMA20062952275228516705109
   PubMed Web of Science ®Google Scholar
• ZinkAAsklingJDixonWGEuropean biologicals registers: methodology, selected results and perspectivesAnn Rheum Dis2009681240124618647854
   PubMed Web of Science ®Google Scholar
• NanniniCCantiniFNiccoliLSingle-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy:is there a need for more comprehensive screening procedures?Arthritis Rheum20096180181219479708
   PubMed Web of Science ®Google Scholar
• LebwohlMBlumRBerkowitzENo evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 yearsArch Dermatol200514186186416027301
   PubMedGoogle Scholar
• WolfeFMichaudKBiologic treatment of rheumatoid arthritis and the risk of malignancy:analyses from a large US observational studyArthritis Rheum2007562886289517729297
   PubMed Web of Science ®Google Scholar
• EllisCNKruegerGGTreatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytesN Engl J Med200134524825511474662
   PubMed Web of Science ®Google Scholar
• KruegerGGClinical response to alefacept:results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasisJ Eur Acad Dermatol Venereol200317Suppl 2172412795771
   PubMed Web of Science ®Google Scholar
• KruegerGGPappKAStoughDBA randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of. 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad Dermatol20024782183312451365
   PubMed Web of Science ®Google Scholar
• LebwohlMChristophersELangleyRAn international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol200313971972712810502
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDKeystoneECAlefacept in combination with methotrexate for the treatment of psoriatic arthritis:results of a randomized, double-blind, placebo-controlled studyArthritis Rheum2006541638164516646026
   PubMed Web of Science ®Google Scholar
• LebwohlMTyringSKHamiltonTKA novel targeted T-cell modulator, efalizumab, for plaque psoriasisN Engl J Med20033492004201314627785
   PubMed Web of Science ®Google Scholar
• JoshiABauerRKueblerPAn overview of the pharmacokinetics and pharmacodynamics of efalizumab:a monoclonal antibody approved for use in psoriasisJ Clin Pharmacol200646102016397279
   PubMed Web of Science ®Google Scholar
• Guttman-YasskyEVugmeysterYLowesMABlockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsivenessJ Invest Dermatol20081281182119118239614
   PubMed Web of Science ®Google Scholar
• OrtonneJPShearNShumackSImpact of efalizumab on patient-reported outcomes in high-need psoriasis patients:results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]BMC Dermatol200551316359548
   PubMedGoogle Scholar
• DubertretLSterryWBosJDCLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis:results from a phase III international randomized, placebo-controlled trialBr J Dermatol200615517018116792770
   PubMed Web of Science ®Google Scholar
• LeonardiCLPappKAGordonKBExtended efalizumab therapy improves chronic plaque psoriasis:results from a randomized phase III trialJ Am Acad Dermatol20055242543315761420
   PubMed Web of Science ®Google Scholar
• PappKABressinckRFretzinSSafety of efalizumab in adults with chronic moderate to severe plaque psoriasis:a phase IIIb, randomized, controlled trialInt J Dermatol20064560561416700803
   PubMed Web of Science ®Google Scholar
• PariserDMGordonKBPappKAClinical efficacy of efalizumab in patients with chronic plaque psoriasis:results from three randomized placebo-controlled Phase III trials:part IJ Cutan Med Surg2005930331216699904
   PubMed Web of Science ®Google Scholar
• PappKACaroILeungHMEfalizumab for the treatment of psoriatic arthritisJ Cutan Med Surg200711576617374316
   PubMed Web of Science ®Google Scholar
• PugashettiRKooJEfalizumab discontinuation:a practical strategyJ Dermatolog Treat20092013213619459081
   PubMed Web of Science ®Google Scholar
• MajorEOProgressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory TherapiesAnnu Rev Med201061354719719397
   PubMed Web of Science ®Google Scholar
• RobertsonMJRitzJInterleukin. 12:Basic Biology and Potential Applications in Cancer TreatmentOncologist19961889710387973
   PubMedGoogle Scholar
• MiossecPKornTKuchrooVKInterleukin-17 and type. 17 helper T cellsN Engl J Med200936188889819710487
   PubMed Web of Science ®Google Scholar
• BlauveltAT-helper. 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasisJ Invest Dermatol2008128106410718408745
   PubMed Web of Science ®Google Scholar
• KruegerGGLangleyRGLeonardiCA human interleukin-12/23 monoclonal antibody for the treatment of psoriasisN Engl J Med200735658059217287478
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX. 1)Lancet20083711665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX. 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin. 12/23 monoclonal antibody, for psoriatic arthritis:randomised, double-blind, placebo-controlled, crossover trialLancet200937363364019217154
   PubMed Web of Science ®Google Scholar
• DixonWGWatsonKLuntMRates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy:results from the British Society for Rheumatology Biologics RegisterArthritis Rheum2006542368237616868999
   PubMed Web of Science ®Google Scholar
• DixonWGWatsonKDLuntMReduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy:results from the British Society for Rheumatology Biologics RegisterArthritis Rheum2007562905291217763428
   PubMed Web of Science ®Google Scholar
• HyrichKLSymmonsDPWatsonKDPregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population registerArthritis Rheum2006542701270216871549
   PubMed Web of Science ®Google Scholar
• ChoyEHHazlemanBSmithMEfficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis:a phase II double-blinded, randomized, dose-escalating trialRheumatology (Oxford)2002411133113712364632
   PubMed Web of Science ®Google Scholar
• MelmedGYTarganSRYasothanUCertolizumab pegolNat Rev Drug Discov2008764164218670430
   PubMed Web of Science ®Google Scholar
• GladmanDKavanaughAMcInnesIGolimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis:Nail, enthesitis, and dactylitis response in the randomized, placebo controlled, GO-REVEAL study. (Abstract)Ann Rheum Dis200867Suppl II
   Google Scholar
• KimballABGordonKBLangleyRGSafety and efficacy of ABT-874, a fully human interleukin. 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis:results of a randomized, placebo-controlled, phase. 2 trialArch Dermatol200814420020718283176
   PubMed Web of Science ®Google Scholar
• ZhengYDanilenkoDMValdezPInterleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosisNature200744564865117187052
   PubMed Web of Science ®Google Scholar
• NestleFOKaplanDHBarkerJPsoriasisN Engl J Med200936149650919641206
   PubMed Web of Science ®Google Scholar
• ZabaLCSuarez-FarinasMFuentes-DuculanJEffective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJ Allergy Clin Immunol200912495102210e139519895991
   PubMed Web of Science ®Google Scholar
• AbdelnoorAMPatented small molecules against psoriasisExpert Opin Ther Pat2009191057107119566378
   PubMed Web of Science ®Google Scholar
• PappKBissonnetteRRosophLEfficacy of ISA247 in plaque psoriasis:a randomised, multicentre, double-blind, placebo-controlled phase III studyLancet20083711337134218424323
   PubMed Web of Science ®Google Scholar
• BorieDCO’SheaJJChangelianPSJAK3 inhibition, a viable new modality of immunosuppression for solid organ transplantsTrends Mol Med20041053254115519279
   PubMed Web of Science ®Google Scholar
• BhagwatSSKinase inhibitors for the treatment of inflammatory and autoimmune disordersPurinergic Signal2009510711518568424
   PubMed Web of Science ®Google Scholar
• BoyMGWangCWilkinsonBEDouble-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasisJ Invest Dermatol20091292299230219225543
   PubMed Web of Science ®Google Scholar